Infant Bacterial Therapeutics Overview

  • Founded
  • 2013

Founded
  • Status
  • Public

  • Employees
  • 8

Employees
  • Stock Symbol
  • IBT B

Stock Symbol
  • Share Price
  • $5.26

  • (As of Wednesday Closing)

Infant Bacterial Therapeutics General Information

Description

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
STO
Primary Office
  • Gamla Brogatan 11
  • 111 20 Stockholm
  • Sweden
+46 08-410 000 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Infant Bacterial Therapeutics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.26 $4.93 $4.65 - $7.85 $55.4M 11.2M 3.83K -$0.38

Infant Bacterial Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 24,863 38,542 101,662 125,199
Revenue 0 0 0 0
EBITDA (4,171) (5,096) (7,711) (4,904)
Net Income (4,298) (5,239) (7,810) (4,897)
Total Assets 35,562 45,137 54,896 55,432
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Infant Bacterial Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Infant Bacterial Therapeutics‘s full profile, request access.

Request a free trial

Infant Bacterial Therapeutics Patents

Infant Bacterial Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016208007-B2 A method of activating lactic acid bacteria Active 14-Jan-2015 0000000000
CA-2972963-A1 A method of activating lactic acid bacteria Pending 14-Jan-2015 0000000000
EP-3244903-A1 A method of activating lactic acid bacteria Pending 14-Jan-2015 0000000000
US-20170304376-A1 Method of activating lactic acid bacteria Pending 14-Jan-2015 0000000000
AU-2016208007-A1 A method of activating lactic acid bacteria Active 14-Jan-2015 A61K9/0053
To view Infant Bacterial Therapeutics’s complete patent history, request access »

Infant Bacterial Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Maria Ekdahl Chief Financial Officer
Robert Molander Chief Commercial Officer
Staffan Strömberg Ph.D Chief Executive Officer
Michael Owens Chief Financial Officer
Anders Kronström Chief Technology Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Infant Bacterial Therapeutics Board Members (4)

Name Representing Role Since
000000 000000000 Infant Bacterial Therapeutics Board Member 000 0000
You’re viewing 1 of 4 board members. Get the full list »

Infant Bacterial Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial